These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial. Cummings J; Isaacson S; Mills R; Williams H; Chi-Burris K; Corbett A; Dhall R; Ballard C Lancet; 2014 Feb; 383(9916):533-40. PubMed ID: 24183563 [TBL] [Abstract][Full Text] [Related]
7. Changing the treatment paradigm for Parkinson's disease psychosis with pimavanserin. Lyons KE; Pahwa R; Hermanowicz N; Davis T; Pagan F; Isaacson S Expert Rev Clin Pharmacol; 2019 Jul; 12(7):681-691. PubMed ID: 31159608 [No Abstract] [Full Text] [Related]
8. Treatment Possibilities for Psychosis in Parkinson's Disease with An Emphasis on the Newly Approved Drug: Pimavanserin. Majlath Z; Obal I; Vecsei L CNS Neurol Disord Drug Targets; 2017; 16(3):234-243. PubMed ID: 27719624 [TBL] [Abstract][Full Text] [Related]
9. Pimavanserin: A Novel Antipsychotic for Parkinson's Disease Psychosis. Bozymski KM; Lowe DK; Pasternak KM; Gatesman TL; Crouse EL Ann Pharmacother; 2017 Jun; 51(6):479-487. PubMed ID: 28375643 [TBL] [Abstract][Full Text] [Related]
10. Pimavanserin, a serotonin(2A) receptor inverse agonist, for the treatment of parkinson's disease psychosis. Meltzer HY; Mills R; Revell S; Williams H; Johnson A; Bahr D; Friedman JH Neuropsychopharmacology; 2010 Mar; 35(4):881-92. PubMed ID: 19907417 [TBL] [Abstract][Full Text] [Related]
11. On the discovery and development of pimavanserin: a novel drug candidate for Parkinson's psychosis. Hacksell U; Burstein ES; McFarland K; Mills RG; Williams H Neurochem Res; 2014 Oct; 39(10):2008-17. PubMed ID: 24682754 [TBL] [Abstract][Full Text] [Related]
12. Pimavanserin: First Global Approval. Markham A Drugs; 2016 Jul; 76(10):1053-7. PubMed ID: 27262680 [TBL] [Abstract][Full Text] [Related]
13. Pimavanserin: An Inverse Agonist Antipsychotic Drug. Howland RH J Psychosoc Nurs Ment Health Serv; 2016 Jun; 54(6):21-4. PubMed ID: 27245248 [TBL] [Abstract][Full Text] [Related]
14. Treating Hallucinations and Delusions Associated With Parkinson's Disease Psychosis. Panchal SC; Ondo WG Curr Psychiatry Rep; 2018 Jan; 20(1):3. PubMed ID: 29374325 [TBL] [Abstract][Full Text] [Related]
15. Pimavanserin, a 5-HT2A inverse agonist, reverses psychosis-like behaviors in a rodent model of Parkinson's disease. McFarland K; Price DL; Bonhaus DW Behav Pharmacol; 2011 Oct; 22(7):681-92. PubMed ID: 21921840 [TBL] [Abstract][Full Text] [Related]
16. Guidance for switching from off-label antipsychotics to pimavanserin for Parkinson's disease psychosis: an expert consensus. Black KJ; Nasrallah H; Isaacson S; Stacy M; Pahwa R; Adler CH; Alva G; Cooney JW; Kremens D; Menza MA; Meyer JM; Patkar AA; Simuni T; Morrissette DA; Stahl SM CNS Spectr; 2018 Dec; 23(6):402-413. PubMed ID: 30588905 [TBL] [Abstract][Full Text] [Related]
17. Successful treatment of clozapine-nonresponsive refractory hallucinations and delusions with pimavanserin, a serotonin 5HT-2A receptor inverse agonist. Nasrallah HA; Fedora R; Morton R Schizophr Res; 2019 Jun; 208():217-220. PubMed ID: 30837203 [TBL] [Abstract][Full Text] [Related]
18. Mechanism of action of pimavanserin in Parkinson's disease psychosis: targeting serotonin 5HT2A and 5HT2C receptors. Stahl SM CNS Spectr; 2016 Aug; 21(4):271-5. PubMed ID: 27503570 [TBL] [Abstract][Full Text] [Related]
19. Blinded SAPS-PD Assessment After 10 Weeks of Pimavanserin Treatment for Parkinson's Disease Psychosis. Isaacson SH; Coate B; Norton J; Stankovic S J Parkinsons Dis; 2020; 10(4):1389-1396. PubMed ID: 32716320 [TBL] [Abstract][Full Text] [Related]
20. The safety, tolerability and efficacy of pimavanserin tartrate in the treatment of psychosis in Parkinson's disease. Hermanowicz S; Hermanowicz N Expert Rev Neurother; 2016 Jun; 16(6):625-33. PubMed ID: 26908168 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]